Related Experiment Video
Updated: Aug 14, 2026
05:36
Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
Published on: February 23, 2024
Deferiprone: New insight
A Piga1, S Roggero, T Vinciguerra
1Department of Pediatric Hematology/Oncology, University of Turin, Turin, Italy. antonio.piga@unito.it
Annals of the New York Academy of Sciences
|December 13, 2005
Summary
Deferiprone shows greater cardioprotection than deferoxamine, improving heart health in iron overload patients. Combining chelators may speed up iron reduction and reverse heart disease, but requires further study.
Area of Science:
- Hematology
- Cardiology
- Pharmacology
Background:
- Iron overload is a significant concern in various medical conditions.
- Deferoxamine and deferiprone are key iron chelators used in treatment.
- Cardiotoxicity is a major complication of iron overload.
Purpose of the Study:
- To compare the cardioprotective effects of deferiprone versus deferoxamine.
- To evaluate the efficacy of combined chelation therapy in iron overload.
- To assess the impact of chelation on myocardial health and iron excretion.
Main Methods:
- Retrospective analysis of patient data.
- Review of myocardial magnetic resonance imaging (MRI) findings.
- Observation of treatment outcomes in patients receiving single or combined chelation therapy.
Main Results:
- Deferiprone demonstrates superior cardioprotection compared to deferoxamine.
- Patients on long-term deferiprone show improved myocardial MRI patterns.
- Combination therapy with deferiprone and deferoxamine appears to enhance iron excretion and accelerate cardiac recovery.
Conclusions:
- Deferiprone is emerging as a preferred oral iron chelator for improving cardiac outcomes.
- Combined chelation therapy shows promise for faster mitigation of iron overload and reversal of heart disease.
- Further randomized controlled trials are necessary to confirm these findings and optimize treatment strategies.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:16Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
01:17Drug Absorption: Overview
The process of drug absorption signifies the transition of a drug from its site of administration into the plasma. This process is influenced by various factors, including the route of administration, the anatomy of the absorption site, the mechanism of absorption, gut motility, and the drug's physicochemical properties.
When drugs are injected intravenously, they directly enter the systemic circulation. Alternatively, orally administered drugs navigate through the gastrointestinal (GI) tract.
When drugs are injected intravenously, they directly enter the systemic circulation. Alternatively, orally administered drugs navigate through the gastrointestinal (GI) tract.
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:16Drug Biotransformation: Overview
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
01:28Drug Biotransformation: Overview
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...